HOUSTON, TEXAS - January 28, 2026 (NEWMEDIAWIRE) - Recent reports of Nipah virus (NiV) infections in West Bengal, India, have reignited global concern, prompting public health authorities to prioritize research into this high-mortality pathogen. In response, Sino Biological, Inc. (Shenzhen Stock Exchange: 301047.SZ), a global leader in recombinant technology, has announced the accelerated availability and development of critical research tools to support the global scientific community in combating NiV.

Nipah Virus: A High-Risk Emerging Pathogen

Nipah virus, a member of the Paramyxoviridae family, is classified by the World Health Organization (WHO) as a priority pathogen due to its epidemic potential and high fatality rate (estimated between 40% to 75%). With no approved vaccines or specific antiviral treatments currently available, the demand for high-quality, biologically active reagents is critical for developing effective countermeasures.

Comprehensive Reagents for NiV Research

To meet the urgent needs of researchers, Sino Biological has launched a series of high-purity NiV G and F proteins. These proteins are essential for understanding viral entry mechanisms and screening therapeutic antibodies. Additionally, the company is fast-tracking the development of NiV N proteins and pre-fusion and post-fusion F trimer proteins. The N proteins are based on the most recently reported strains, offering improved sequence relevance compared with existing products that contain multiple mutations. In addition to standard proteins, Sino Biological offers ProPure™ endotoxin-free (ET-free) versions of NiV G and F proteins, designed for vaccine research applications where immunogen purity and endotoxin control are critical.

"Our mission is to provide the scientific community with the highest quality tools as rapidly as possible when emerging infectious diseases threaten global health," said Dr. Rob Burgess, Chief Business Officer at Sino Biological US. "By expanding our NiV portfolio, we aim to empower researchers to streamline vaccine discovery and diagnostic breakthroughs."

About Sino Biological

Sino Biological is a global biotechnology company specializing in high-quality recombinant proteins, antibodies, and customized research services. Serving researchers in over 90 countries, Sino Biological supports basic research, drug discovery, vaccine development, and diagnostics through its comprehensive product portfolio, proprietary quality systems, and innovative research platforms.

Forward-Looking Statements

Certain statements in this document are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act. These statements are based on Sino Biological management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may differ materially from those included in these statements due to a variety of factors, over which Sino Biological has no control. Sino Biological assumes no obligation to update these forward-looking statements and does not intend to do so.

For media inquiries or partnership opportunities, please contact:

Sino Biological, Inc.
gmo@sinobiological.cn
www.sinobiological.com
https://www.sinobiological.com/research/virus/nipah-virus
https://www.sinobiological.com/research/virus/niv-proteins-reagent
https://www.sinobiological.com/

View the original release on www.newmediawire.com

This contant was orignally distributed by NewMediaWire. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development.